




RealRate

PHARMACEUTICAL 2019

DMK Pharmaceuticals Corp
Rank 153 of 361



The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 62% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 288%, being 39% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	25,784
Cost of Goods Sold	9,798
Intangible Assets	20,851
Liabilities, Current	11,554
Liabilities, Non-Current	0
Other Assets	1,855
Other Compr. Net Income	0
Other Expenses	-359
Other Liabilities	113
Other Net Income	88
Other Revenues	15,087
Property and Equipment	9,868
Research and Development	18,794
Selling, General and Administrative Expense	25,948

Output Variable	Value in 1000 USD
Assets	58,358
Liabilities	11,666
Expenses	54,181
Revenues	15,087
Stockholders Equity	46,692
Net Income	-39,007
Comprehensive Net Income	-39,007
BaseVar	69,690
ECR before LimitedLiability	179%
Economic Capital Ratio	288%